Avita Medical (RCEL) Stock Price, News & Analysis

Company Overview

Avita Medical, Inc. (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S. Food and Drug Administration for acute thermal burn wounds. The company has since expanded its clinical indications and market access efforts into regions such as Australia, China and other parts of Asia. Avita collaborates with leading burn centers, academic institutions and investigator‐initiated trials to explore additional applications—ranging from chronic diabetic ulcers to vitiligo and hair restoration.

Under the leadership of President and Chief Executive Officer Michael Perry, Avita Medical has emphasized the integration of its proprietary cell‐harvesting technology into standard burn and wound care protocols. The company maintains a global commercial infrastructure to support physician training, clinical research, and post‐market surveillance. Its strategic priorities include broadening clinical adoption of ReCell, pursuing new regulatory approvals and fostering partnerships to extend its regenerative platform into adjacent markets.

Key Stats

• Today's Range: $5.19 to $5.37
• 50-Day Range: $4.17 to $6.76
• 52-Week Range: $3.60 to $14.16
• Volume: 60,125 shs
• Average Volume: 286,536 shs
• Market Capitalization: $141.88 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.60
• Consensus Rating: Hold

Avita Medical Stock Analysis - MarketRank™

Avita Medical scored higher than 47% of companies evaluated by MarketBeat, and ranked 618th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Hold

Consensus Rating

Avita Medical has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 3 buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

Avita Medical has a consensus price target of $11.60, representing about 117.6% upside from its current price of $5.33.

Amount of Analyst Coverage

Avita Medical has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Avita Medical are expected to grow in the coming year, from ($0.95) to ($0.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avita Medical is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avita Medical is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avita Medical has a P/B Ratio of 31.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

18.47% of the float of Avita Medical has been sold short.

Short Interest Ratio / Days to Cover

Avita Medical has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Avita Medical has recently decreased by 1.52%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avita Medical does not currently pay a dividend.

Dividend Growth

Avita Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

18.47% of the float of Avita Medical has been sold short.

Short Interest Ratio / Days to Cover

Avita Medical has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Avita Medical has recently decreased by 1.52%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.42

News Sentiment

Avita Medical has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Avita Medical this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for RCEL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Avita Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $113,660.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.80% of the stock of Avita Medical is held by insiders.

Percentage Held by Institutions

Only 27.66% of the stock of Avita Medical is held by institutions.

RCEL Stock Analysis - Frequently Asked Questions

How have RCEL shares performed this year?

Avita Medical's stock was trading at $12.80 at the beginning of 2025. Since then, RCEL stock has decreased by 58.4% and is now trading at $5.33.

How were Avita Medical's earnings last quarter?

Avita Medical Inc. (NASDAQ:RCEL) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.12. The firm had revenue of $18.42 million for the quarter, compared to analyst estimates of $34.27 million. Avita Medical had a negative trailing twelve-month return on equity of 632.62% and a negative net margin of 68.87%.
Read the conference call transcript.

Who are Avita Medical's major shareholders?

Top institutional investors of Avita Medical include Farther Finance Advisors LLC (0.02%). Insiders that own company stock include Michael S Perry, Robert Mcnamara, Donna Shiroma, Suzanne Crowe, Jeremy Curnock Cook and James Corbett.
View institutional ownership trends.

How do I buy shares of Avita Medical?

Shares of RCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Avita Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Avita Medical investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Tesla (TSLA).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:RCEL
• CIK: 1762303
• Web: www.avitamedical.com
• Phone: (833) 462-8482
• Fax: N/A
• Employees: 130
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Avita Medical: $11.60
• High Price Target: $21.00
• Low Price Target: $3.00
• Potential Upside/Downside: +121.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$61.85 million
• Net Margins: -68.87%
• Pretax Margin: -68.87%
• Return on Equity: -632.62%
• Return on Assets: -71.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.58
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: $64.25 million
• Price / Sales: 2.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.17 per share
• Price / Book: 30.85

Miscellaneous

• Outstanding Shares: 26,620,000
• Free Float: 25,874,000
• Market Cap: $139.62 million
• Optionable: Optionable
• Beta: 1.64